| DNA repair targeted therapy: The past or future of cancer treatment? NS Gavande, PS VanderVere-Carozza, HD Hinshaw, SI Jalal, CR Sears, ... Pharmacology & therapeutics 160, 65-83, 2016 | 400 | 2016 |
| Modulating DNA repair pathways to improve precision genome engineering KS Pawelczak, NS Gavande, PS VanderVere-Carozza, JJ Turchi ACS chemical biology 13 (2), 389-396, 2018 | 134 | 2018 |
| 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor α and-γ (PPARα and γ) dual agonists N Gavande, A Matin, MS Kim, NX Yang, NK Salam, JR Hanrahan, ... Journal of medicinal chemistry 52 (21), 6835-6850, 2009 | 112 | 2009 |
| Regulation of Low‐Density Lipoprotein Receptor and 3‐Hydroxy‐3‐Methylglutaryl Coenzyme A Reductase Expression by Zingiber officinale in the Liver of High … S Nammi, MS Kim, NS Gavande, GQ Li, BD Roufogalis Basic & clinical pharmacology & toxicology 106 (5), 389-395, 2010 | 85 | 2010 |
| The enantiomers of syn-2, 3-difluoro-4-aminobutyric acid elicit opposite responses at the GABA C receptor I Yamamoto, MJT Jordan, N Gavande, MR Doddareddy, M Chebib, ... Chemical communications 48 (6), 829-831, 2012 | 65 | 2012 |
| 2′‐Methoxy‐6‐methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABAA receptors N Karim, J Curmi, N Gavande, GAR Johnston, JR Hanrahan, ML Tierney, ... British journal of pharmacology 165 (4), 880-896, 2012 | 55 | 2012 |
| 3-Hydroxy-2′-methoxy-6-methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes N Karim, N Gavande, P Wellendorph, GAR Johnston, JR Hanrahan, ... Biochemical pharmacology 82 (12), 1971-1983, 2011 | 48 | 2011 |
| Structure-based design of highly selective β-secretase inhibitors: synthesis, biological evaluation, and protein–ligand x-ray crystal structure AK Ghosh, K Venkateswara Rao, ND Yadav, DD Anderson, N Gavande, ... Journal of medicinal chemistry 55 (21), 9195-9207, 2012 | 40 | 2012 |
| Medicinal chemistry of ρ GABAC receptors CKL Ng, H Kim, N Gavande, I Yamamoto, RJ Kumar, KN Mewett, ... Future medicinal chemistry 3 (2), 197-209, 2011 | 37 | 2011 |
| Recent developments in the deoxyfluorination of alcohols and phenols: new reagents, mechanistic insights, and applications WL Hu, XG Hu, L Hunter Synthesis 49 (22), 4917-4930, 2017 | 35 | 2017 |
| Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors D Das, K Maeda, Y Hayashi, N Gavande, DV Desai, SB Chang, AK Ghosh, ... Antimicrobial Agents and Chemotherapy 59 (4), 1895-1904, 2015 | 34 | 2015 |
| Novel cyclic phosphinic acids as GABAC ρ receptor antagonists: design, synthesis, and pharmacology N Gavande, I Yamamoto, NK Salam, TH Ai, PM Burden, GAR Johnston, ... ACS medicinal chemistry letters 2 (1), 11-16, 2011 | 34 | 2011 |
| Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of ρ1 GABAC Receptors N Gavande, HL Kim, MR Doddareddy, GAR Johnston, M Chebib, ... ACS Medicinal Chemistry Letters 4 (4), 402-407, 2013 | 31 | 2013 |
| Agonist responses of (R)-and (S)-3-fluoro-γ-aminobutyric acids suggest an enantiomeric fold for GABA binding to GABA C receptors I Yamamoto, GP Deniau, N Gavande, M Chebib, GAR Johnston, ... Chemical communications 47 (28), 7956-7958, 2011 | 29 | 2011 |
| Guanidino Acids Act as ρ1 GABAC Receptor Antagonists M Chebib, N Gavande, KY Wong, A Park, I Premoli, KN Mewett, RD Allan, ... Neurochemical research 34, 1704-1711, 2009 | 26 | 2009 |
| PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy JM Kelm, DS Pandey, E Malin, H Kansou, S Arora, R Kumar, NS Gavande Molecular Cancer 22 (1), 62, 2023 | 25 | 2023 |
| The flavonoid, 2′-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia AN Clarkson, L Boothman-Burrell, Z Dósa, RY Nagaraja, L Jin, K Parker, ... Journal of Cerebral Blood Flow & Metabolism 39 (7), 1266-1282, 2019 | 24 | 2019 |
| Microwave-enhanced synthesis of 2, 3, 6-trisubstituted pyridazines: application to four-step synthesis of gabazine (SR-95531) N Gavande, GAR Johnston, JR Hanrahan, M Chebib Organic & Biomolecular Chemistry 8 (18), 4131-4136, 2010 | 24 | 2010 |
| Design, synthesis, biological evaluation of 3, 5-diaryl-4, 5-dihydro-1H-pyrazole carbaldehydes as non-purine xanthine oxidase inhibitors: Tracing the anticancer mechanism via … G Joshi, M Sharma, S Kalra, NS Gavande, S Singh, R Kumar Bioorganic Chemistry 107, 104620, 2021 | 23 | 2021 |
| The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists A Matin, MR Doddareddy, N Gavande, S Nammi, PW Groundwater, ... Bioorganic & medicinal chemistry 21 (3), 766-778, 2013 | 23 | 2013 |
